Literature DB >> 12152115

Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users.

P C Souverein1, A C G Egberts, E J H Meuleman, J Urquhart, H G M Leufkens.   

Abstract

Sildenafil utilization was prospectively evaluated among 153 men with a history of erectile dysfunction (ED)-prescription drug use prior to starting sildenafil and 164 men who were new starters of ED-prescription drugs. Further, some determinants of sildenafil discontinuation were identified. During a median follow-up period of 18 months 45% of all patients discontinued sildenafil treatment, regardless of earlier treatment history. However, patients with a history of drug treatment for ED were nearly eight times as likely to switch or re-start another ED-prescription drug after discontinuing sildenafil compared to previously untreated users. Age >60 y, diabetes medication, nitrate use, and use of incontinence pads (a proxy for disease/surgery in the pelvic region) were associated with an increased likelihood of discontinuing sildenafil. Although the introduction of sildenafil reduced the barrier to seek medical help for erectile problems, sildenafil treatment failure in previously untreated patients results in a high dropout rate from further ED drug treatment of any kind.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12152115     DOI: 10.1038/sj.ijir.3900883

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  12 in total

Review 1.  [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].

Authors:  H Porst
Journal:  Urologe A       Date:  2004-07       Impact factor: 0.639

Review 2.  Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.

Authors:  Mary Lee; Roohollah Sharifi
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

Review 3.  Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior.

Authors:  Hans Hedelin; Peter Ströberg
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Effects of Ginkgo biloba extracts with mirodenafil on the relaxation of corpus cavernosal smooth muscle and the potassium channel activity of corporal smooth muscle cells.

Authors:  Jung Jun Kim; Deok Hyun Han; Soo Hyun Lim; Tae Hun Kim; Mee Ree Chae; Kyung Jin Chung; Sung Chul Kam; Ju-Hong Jeon; Jong Kwan Park; Sung Won Lee
Journal:  Asian J Androl       Date:  2011-04-11       Impact factor: 3.285

Review 5.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  [Therapy of erectile dysfunction in 2005].

Authors:  H Porst
Journal:  Urologe A       Date:  2003-10       Impact factor: 0.639

Review 7.  A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction.

Authors:  Min Chul Cho; Jae-Seung Paick
Journal:  Ther Adv Urol       Date:  2016-01-19

Review 8.  Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review.

Authors:  Paul Williams; Hayley McBain; Aliya Amirova; Stanton Newman; Kathleen Mulligan
Journal:  Int J Impot Res       Date:  2020-03-31       Impact factor: 2.896

9.  Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.

Authors:  Konstantinos Giannitsas; Angelis Konstantinopoulos; Christos Patsialas; Petros Perimenis
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

10.  Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients.

Authors:  S-C Kim; Y-S Lee; K-K Seo; G-W Jung; T-H Kim
Journal:  Int J Impot Res       Date:  2013-12-05       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.